AC 699
Alternative Names: AC-0699; AC-699Latest Information Update: 19 Aug 2024
At a glance
- Originator Accutar Biotechnology
- Class Antineoplastics
- Mechanism of Action Estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 negative breast cancer
Most Recent Events
- 14 Aug 2024 AC 699 receives Fast Track designation for HER2-negative-breast-cancer [PO] (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA
- 03 Jun 2024 Efficacy and adverse events data from a phase I trial in HER2-negative-breast-cancer released by Accutar Biotechnology
- 31 May 2024 Accutar Biotechnology plans a phase II trial for HER2-negative-breast-cancer in early 2024